Analysts Expect Thermo Fisher Scientific Inc. (TMO) Will Announce Quarterly Sales of $6.24 Billion

Share on StockTwits

Wall Street brokerages expect Thermo Fisher Scientific Inc. (NYSE:TMO) to announce sales of $6.24 billion for the current quarter, according to Zacks. Six analysts have provided estimates for Thermo Fisher Scientific’s earnings, with the highest sales estimate coming in at $6.28 billion and the lowest estimate coming in at $6.21 billion. Thermo Fisher Scientific reported sales of $6.05 billion during the same quarter last year, which would suggest a positive year over year growth rate of 3.1%. The business is scheduled to report its next earnings results on Wednesday, January 30th.

On average, analysts expect that Thermo Fisher Scientific will report full year sales of $24.09 billion for the current fiscal year, with estimates ranging from $24.06 billion to $24.13 billion. For the next financial year, analysts expect that the firm will report sales of $25.20 billion, with estimates ranging from $24.97 billion to $25.62 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.55 by $0.07. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the business posted $2.31 EPS.

A number of equities analysts recently issued reports on TMO shares. Zacks Investment Research lowered Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a research note on Tuesday, July 24th. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, July 24th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $300.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 26th. Leerink Swann raised their target price on Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a research note on Thursday, July 26th. Finally, Morgan Stanley raised their target price on Thermo Fisher Scientific from $233.00 to $242.00 and gave the stock an “overweight” rating in a research note on Thursday, July 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $263.55.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $247.50, for a total transaction of $31,066,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Tyler Jacks sold 4,772 shares of Thermo Fisher Scientific stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $239.75, for a total value of $1,144,087.00. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Pitcairn Co. boosted its holdings in Thermo Fisher Scientific by 1.3% in the 2nd quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock worth $3,495,000 after buying an additional 215 shares during the last quarter. Hall Capital Management Co. Inc. boosted its holdings in Thermo Fisher Scientific by 6.2% in the 3rd quarter. Hall Capital Management Co. Inc. now owns 3,780 shares of the medical research company’s stock worth $923,000 after buying an additional 220 shares during the last quarter. Nvwm LLC boosted its holdings in Thermo Fisher Scientific by 6.1% in the 2nd quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock worth $877,000 after buying an additional 242 shares during the last quarter. Tiedemann Advisors LLC boosted its holdings in Thermo Fisher Scientific by 19.4% in the 2nd quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock worth $315,000 after buying an additional 247 shares during the last quarter. Finally, Chesapeake Wealth Management boosted its holdings in Thermo Fisher Scientific by 6.0% in the 2nd quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock worth $910,000 after buying an additional 249 shares during the last quarter. Hedge funds and other institutional investors own 85.47% of the company’s stock.

TMO stock traded up $0.52 during midday trading on Tuesday, reaching $233.40. The stock had a trading volume of 1,463,514 shares, compared to its average volume of 1,455,515. The firm has a market capitalization of $97.05 billion, a price-to-earnings ratio of 24.59, a price-to-earnings-growth ratio of 1.75 and a beta of 1.08. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.84 and a quick ratio of 1.27. Thermo Fisher Scientific has a 52-week low of $181.51 and a 52-week high of $249.95.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, December 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s payout ratio is currently 7.17%.

Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Friday, September 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Asset Allocation

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply